Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine

EPMA Journal

Volumn 4, Issue 1, 2013, Pages

  Drucker, Elisabeth ^a   Krapfenbauer, Kurt ^b  

^a UNIVERSITY OF APPLIED SCIENCES   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarker perspectives; Predictive medicine; Regulatory overview; Tailored therapy; Targeted prevention; Validation strategies

Indexed keywords

BIOLOGICAL MARKER;

AGE; DIAGNOSTIC TEST; HUMAN; NON INVASIVE PROCEDURE; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; RACE; REVIEW; SAMPLING; SEX; TRANSLATIONAL RESEARCH;

EID: 84979286180     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/1878-5085-4-7     Document Type: Review

References (27)

1. Javle M, Hsueh CT: Recent advances in gastrointestinal oncology—updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol 2010 2009, 23(3):11-23.
2. Poste G: Bring on the biomarkers. Nature 2011, 469:156-157.
3. Waerner T, Urthaler J, Krapfenbauer K: The role of laboratory medicine in healthcare: quality requirements of immunoassays, standardisation and data management in prospective medicine. EPMA J 2010, 1:619-626.
4. Golubnitschaja O, Costigliola V, EPMA: General reports & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J 2012, 3:14.
5. Issaq HJ, Waybright TJ, Veenstra TD: Cancer biomarker discovery: opportunities and pitfalls in analytical methods. Electrophoresis 2011, 32(9):967-975.
6. Amur S, Frueh FW, Lesko LJ, Huang SM: Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med 2008, 2(3):305-311.
7. Feuerstein GZ, Dormer C Jr, Rufollo RR, Stiles G, Walsh FS, Rutkowski JL: Translational medicine perspectives of biomarkers in drug discovery and development. Part I. Target selection and validation - biomarkers take center stage. Int Drug Discovery 2007, 2(5):36-43.
8. Bruenner N: What is the difference between “predictive and prognostic biomarkers”? Can you give some examples? Connection 2009, 13:18.
9. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A: Biomarkers and surrogate end points - the challenge of statistical validation. Nat Rev Clin Oncol 2007, 7(6):309-317.
10. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A: Integrating biomarkers in clinical trials. Expert Rev Mol Diagn 2011, 11(2):171-182.
11. Rosenkranz B: Biomarkers and surrogate end points in clinical drug development. Appl Clin Trials 2003, 5(2):30-40.
12. Lassere MN, Johnson KR, Boers M: Definitions and validation criteria for biomarkers and surrogate end points: development and testing of a quantitative hierarchical level of evidence schema. J Rheumatol 2007, 34(3):607-615.
13. Atkinson AJ, Colburn WA, DeGruttola VG: Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95.
14. Frank R, Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003, 2(7):566-580.
15. Zolg W: The proteomic search for diagnostic biomarkers: molecular & cellular. Proteomics 2006, 5:10. 1720-1726.
16. Goodsaid FM, Mendrick DL: Translational medicine and the value of biomarker qualification. Sci Transl Med 2010, 2(47):47.
17. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061.
18. Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A: Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol 2009, 43:461-466.
19. Lawton KA, Berger A, Mitchell M, Milgram KE, Evans AM, Guo L, Hanson RW, Kalhan SC, Ryals JA, Milburn MV: Analysis of the adult human plasma metabolome. Pharmacogenomics 2008, 9:383-397.
20. Grossman HB: Are biomarkers for bladder cancer beneficial? J Urol 2010, 183:11-12.
21. Want EJ, O’Maille G, Smith CA, Brandon TR, Uritboonthai W, Qin C, Trauger SA, Siuzdak G: Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal Chem 2006, 78:743-752.
22. Xiao Z, Conrads TP, Lucas DA, Janini GM, Schaefer CF, Buetow KH, Issaq HJ, Veenstra TD: Direct ampholyte-free liquid-phase isoelectric peptide focusing: application to the human serum proteome. Electrophoresis 2004, 25:128-133.
23. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A: The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004, 3:311-326.
24. Buscher JM, Czernik D, Ewald JC, Sauer U, Zamboni N: Cross-platform comparison of methods for quantitative metabolomics of primary metabolism. Anal Chem 2009, 81:2135-2143.
25. Sleigh S, Barton C: Advances in Drug-Diagnostic Co-Development. London: Scrip Business Insights; 2011.
26. Ausweger C, Burgschwaiger E, Kugler A, Schmidbauer R, Steinek I, Todorov Y, Thurnher D, Krapfenbauer K: Economic concerns about global healthcare in lung, head and neck cancer: meeting the economic challenge of predictive, preventive and personalized medicine. EPMA J 2010, 1(4):627-631.
27. Koehn J, Krapfenbauer K: Advanced proteomics procedure as a detection tool for predictive screening in type 2 pre-diabetes. EPMA J 2010, 1(1):19-31.